The DOI matches its Crossref record; 368 of the 371 references it cites were found in a registry or an index.
EASL Clinical Practice Guidelines: Drug-induced liver injury
Abstract
Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drug-induced liver injury (DILI) is an uncommon adverse reaction to drugs, and other chemicals, including herbal and dietary supplements (HDS).”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“The vast majority of cases of DILI occur at therapeutic doses in a small proportion of individuals exposed to the drug, representing an idiosyncratic reaction, and therefore unpredictable based on the drug's mechanism of action and related to the uniqueness of the individual [1,2].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“In pediatric medicine, DILI is a rare clinical situation. However, it has high morbidity and mortality, and it is one of the most common causes of acute liver failure. Furthermore, its diagnosis is clinically challenging due to its low incidence and phenotypic variability [6,7,8].”
From Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM (2023) · cites this paper as [7]
In the citing paper
“The lack of a reliable diagnostic biomarker and evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“The lack of reliable diagnostic biomarkers and an evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.2,25–27”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“However, drug rechallenge in DILI cases is potentially dangerous2,75 and is associated with risk of death or requirement for liver transplant.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“High TBil and ALP levels in the second month after an acute DILI episode and the biochemical nonresolution-6 model may help predict the risk of chronic injury and delayed recovery [26,72].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Its potential value in confirming or excluding hepatocellular injury in cases of elevated ALT levels from a suspected extrahepatic origin (e.g., muscle) has been evaluated [26,175].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Ekor, M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00177 · Cited by 3,919
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Acetaminophen‐induced acute liver failure
Larson, A. M., Polson, J., Fontana, R. J., Davern, T. J., Lalani, E., Hynan, L. S., REISCH, J. S., Schiødt, F. V., Ostapowicz, G., Shakil, A. O., et al. (2005) · Hepatology · doi:10.1002/hep.20948 · Cited by 1,934
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Research works printed but not linked: 5
- Nicoletti, 2017, Genome-wide association study (GWAS) to identify genetic risk factors that increase susceptibility to antituberculosis drug-induced liver injury (ATDILI) [Abstract], Hepatology, 66, A-25
- Lim, 2008, Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review, Neurol Asia, 13, 15
- US Food & Drug Administration, 2017, Drugs
- Sanjuan-Jimenez, 2017, Prevalence of hepatitis E markers in Spanish patients with suspected drug-induced liver injury [abstract], Hepatology, 66, 423A
- Fernández-Castañer, 2008, An analysis of the causes, characteristics, and consequences of reexposure to a drug or compound responsible for a hepatotoxicity event, Rev Esp Enfermedades Dig, 100, 278
Cited by
Sorted by citations
Items 101–200 of 1,279
Gatti, M., Fusaroli, M., Caraceni, P., Poluzzi, E., Ponti, F. D., & Raschi, E. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14459 · Cited by 48
Shen, X.-L., Guo, Y.-N., Lu, M.-H., Ding, K., Liang, S.-S., Mou, R.-W., Yuan, S., He, Y., & Tang, L. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.114590 · Cited by 48
Insights into medication-induced liver injury: Understanding and management strategies
Tiwari, V., Shandily, S., Albert, J., Mishra, V. K., Dikkatwar, M. S., Singh, R. M., Sah, S. K., & Chand, S. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101976 · Cited by 48
Raschi, E., & Ponti, F. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01235 · Cited by 48
Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms
Ezhilarasan, D. (2023) · Drug Metabolism Reviews · doi:10.1080/03602532.2023.2215478 · Cited by 47
The Dual Role of Innate Immune Response in Acetaminophen-Induced Liver Injury
Yang, T., Wang, H., Wang, X., Li, J., & Jiang, L. (2022) · Biology · doi:10.3390/biology11071057 · Cited by 47
EASL Clinical Practice Guideline: Occupational liver diseases
Colombo, M., Vecchia, C. L., Lotti, M., Lucena, M. I., Stove, C. P., Paradis, V., & Newsome, P. N. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.008 · Cited by 46
Effects of Anthraquinones on Immune Responses and Inflammatory Diseases
Xin, D., Li, H., Zhou, S., Zhong, H., & Pu, W. (2022) · Molecules · doi:10.3390/molecules27123831 · Cited by 43
Alpers, D., Lewis, J. H., Hunt, C. M., Freston, J. W., Torres, V. E., Li, H., Wang, W., Hoke, M. E., Roth, S. E., Westcott‐Baker, L., et al. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.08.012 · Cited by 45
Hepatotoxicity of immune check point inhibitors: Approach and management
Lleò, A., Rimassa, L., & Colombo, M. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.06.017 · Cited by 44
Sex disparity and drug-induced liver injury
Floreani, A., Bizzaro, D., Shalaby, S., Taliani, G., & Burra, P. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.06.025 · Cited by 43
Ziogas, D. C., Gkoufa, A., Cholongitas, Ε., Diamantopoulos, P. T., Anastasopoulou, A. N., Ascierto, P. A., & Gogas, H. J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001322 · Cited by 43
Treem, W. R., Palmer, M., Lonjon‐Domanec, I., Seekins, D. W., Dimick‐Santos, L., Avigan, M., MARCINAK, J. F., Dash, A., Regev, A., Maller, E. S., et al. (2020) · Drug Safety · doi:10.1007/s40264-020-01014-2 · Cited by 43
Self-citationAI/ML Models to Predict the Severity of Drug-Induced Liver Injury for Small Molecules
Rao, M. S., Nassiri, V., Alhambra, C., Snoeys, J., Goethem, F. V., Irrechukwu, O., Aleo, M. D., Geys, H., Mitra, K., & Will, Y. (2023) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.3c00098 · Cited by 42
Advances in the study of acetaminophen-induced liver injury
Li, X., Ni, J., & Chen, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1239395 · Cited by 42
López-Pascual, E., Rienda, I., Pérez‐Rojas, J., Rapisarda, A. S., García-Llorens, G., Jover, R., & Castell, J. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105203 · Cited by 42
NAFLD and autoimmune hepatitis: Do not judge a book by its cover
Dalekos, G. Ν., Gatselis, N., Zachou, K., & Koukoulis, G. Κ. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.02.001 · Cited by 42
Advancements in stem cell-derived hepatocyte-like cell models for hepatotoxicity testing
Jin, M., Xiao, Y., Liao, W., Chen, Q., Yang, W., Li, Y., Li, S., Gao, Y., Peng, Q., & Zhou, S. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02152-9 · Cited by 41
Chronic Drug-Induced Liver Injury: Updates and Future Challenges
Wang, Q., Huang, A., Wang, J., & Zou, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.627133 · Cited by 41
Herb-Induced Liver Injury—A Challenging Diagnosis
Nunes, D. R. D. C. M. A., Monteiro, C. S. D. J., & dos Santos, J. L. (2022) · Healthcare · doi:10.3390/healthcare10020278 · Cited by 40
Li, Q., Chen, F., & Wang, F. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00921-4 · Cited by 40
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
Gatti, M., Poluzzi, E., Ponti, F. D., & Raschi, E. (2020) · Drug Safety · doi:10.1007/s40264-020-00975-8 · Cited by 40
Kumachev, A., & Wu, P. E. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.202026 · Cited by 39
British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis
Gleeson, D. C., Bornand, R., Brownlee, A., Dhaliwal, H., Dyson, J. K., Hails, J., Henderson, P., Kelly, D. A., Mells, G. F., Miquel, R., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-333171 · Cited by 44
Suh, J. I. (2019) · Journal of Yeungnam Medical Science · doi:10.12701/yujm.2019.00297 · Cited by 39
Impact of genetic and environmental factors on autoimmune hepatitis
Zachou, K., Arvaniti, P., Lyberopoulou, A., & Dalekos, G. N. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100125 · Cited by 39
Niu, H., Ma, J., Medina‐Caliz, I., Robles‐Diaz, M., Bonilla‐Toyos, E., Ghabril, M., Lucena, M. I., Alvarez‐Alvarez, I., & Andrade, R. J. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17373 · Cited by 37
Self-citationTherapeutics for treating mpox in humans
Fox, T., Gould, S., Zacchaeus, N. G. P., Rowland, T., Lutje, V., & Kuehn, R. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015769 · Cited by 39
Ito, T., Ishigami, M., Yamamoto, T., Mizuno, K., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Kawashima, H., Yasuda, S., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10238-y · Cited by 38
The Management of Glucocorticoid Therapy in Liver Failure
Xue, R., & Meng, Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02490 · Cited by 37
Immunotherapy-induced Hepatotoxicity: A Review
Cunha, T. D., Wu, G. Y., & Vaziri, H. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00105 · Cited by 37
Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances
Zhao, L., Tang, H., & Cheng, Z. (2024) · Pharmaceuticals · doi:10.3390/ph17121724 · Cited by 37
Xiao, L., Zhang, F., Zhao, Y., Zhang, L., Xie, Z., Huang, K., Ouyang, X., Wu, X., Xu, X., & Li, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-75141-2 · Cited by 37
Umbaugh, D. S., & Jaeschke, H. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1857238 · Cited by 37
Alidadi, M., Sahebkar, A., Eslami, S., Vakilian, F., Jarahi, L., Alinezhad‐Namaghi, M., Arabi, S. M., Vakili, S., Tohidinezhad, F., Nikooiyan, Y., et al. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-64872-5_1 · Cited by 37
Han, Y., Black, S. M., Gong, Z., Chen, Z., Ko, J., Zhou, Z., Xia, T., Fang, D., Yang, D., Gu, D., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.017 · Cited by 37
Wang, C., Deng, Y., Li, P., Zheng, S., Chen, G., Zhou, G., Xu, J., Chen, Y., Wang, Z., Jin, X., et al. (2022) · Hepatology · doi:10.1002/hep.32283 · Cited by 28
Zhou, W., He, H., Wei, Q., Che, L., Zhao, X., Liu, W., Yan, Y., Hu, L., Du, Y., Yin, Z., et al. (2023) · Food Science & Nutrition · doi:10.1002/fsn3.3609 · Cited by 36
Lu, Y., Chen, T., Lin, H., Chen, Y., Lin, Y., Le, D., Huang, Y., Wang, A. H. ‐., Lee, C., & Ling, T. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70044 · Cited by 36
From mechanisms to medicine: Ferroptosis as a Therapeutic target in liver disorders
He, Y., Lin, Y., Song, J., Song, M., Nie, X., Sun, H. J., Xu, C., Han, Z., & Cai, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02121-2 · Cited by 36
Tian, Q., Yang, R., Wang, Y., Liu, J., Wee, A., Saxena, R., Wang, L., Li, M., Liu, L., Shan, S., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.067 · Cited by 36
Choi, J. H., Jin, S. W., Lee, G. H., Han, E. H., Hwang, Y. P., & Jeong, H. G. (2021) · Antioxidants · doi:10.3390/antiox10010086 · Cited by 36
Jiang, N., Li, H., Sun, Y., Zeng, J., Yang, F., Kantawong, F., & Wu, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.618522 · Cited by 36
The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury
Liu, W., Zeng, X., Liu, Y., Liu, J., Li, C., Chen, L., Chen, H., & Ouyang, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.723940 · Cited by 37
Alcohol-induced liver injury in signalling pathways and curcumin's therapeutic potential
Subramaniyan, V., Lubau, N. S. A., Mukerjee, N., & Kumarasamy, V. (2023) · Toxicology Reports · doi:10.1016/j.toxrep.2023.10.005 · Cited by 35
Jiang, S., Wang, R., Li, L., Hong, D., Ren-ping, R., Rao, Y., Miao, J., Chen, N., Wu, X., Ye, Z., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00347 · Cited by 35
Xie, Z., Zhang, L., Chen, E., Lü, J., Xiao, L., Liu, Q., Zhu, D., Zhang, F., Xu, X., & Li, L. (2021) · Metabolites · doi:10.3390/metabo11120852 · Cited by 35
Chen, C., Gong, W., Tian, J., Gao, X., Qin, X., Du, G., & Zhou, Y. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.04.016 · Cited by 35
Xiao, Y., Chen, Y., Huang, R., Jiang, F., Zhou, J., & Yang, T. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02214-5 · Cited by 34
Zhao, W., Luo, H., Lin, Z., Huang, L., Pan, Z., Chen, L., Fan, L., Yang, S., Tan, H., Zhong, C., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118364 · Cited by 34
Londoño, M., Reig, M., & on behalf of the RETOINMUNO Multidisciplinary Group (2020) · Cancers · doi:10.3390/cancers12113446 · Cited by 34
Squaramide‐Based Supramolecular Materials Drive HepG2 Spheroid Differentiation
Liu, T., van den Berk, L., Wondergem, J. A. J., Tong, C., Kwakernaak, M. C., ter Braak, B., Heinrich, D., van de Water, B., & Kieltyka, R. E. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001903 · Cited by 34
Wang, J., Huang, A., Wang, Y., Ji, D., Liang, Q., Zhao, J., Zhou, G., Liu, S., Niu, M., Sun, Y., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16902 · Cited by 31
Self-citationMolecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis
Vitale, G., Mattiaccio, A., Conti, A., Berardi, S., Vero, V., Turco, L., Seri, M., & Morelli, M. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065823 · Cited by 33
Singh, D., Khan, M. A., & Siddique, H. R. (2023) · Phytotherapy Research · doi:10.1002/ptr.8022 · Cited by 33
Cunningham, M. E., Iafolla, M. A. J., Kanjanapan, Y., Cerocchi, O., Butler, M. O., Siu, L. L., Bedard, P. L., Ross, K., Hansen, B. E., Spreafico, A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253070 · Cited by 33
Bárdi, E., Mulder, R. L., van Dalen, E. C., Bhatt, N. S., Ruble, K., Burgis, J. C., Castellino, S. M., Constine, L. S., den Hoed, C. M., Green, D. M., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102296 · Cited by 33
Cojutti, P. G., Carnelutti, A., Lazzarotto, D., Sozio, E., Candoni, A., Fanin, R., Tascini, C., & Pea, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122099 · Cited by 33
Pasqua, L. G. D., Cagna, M., Berardo, C., Vairetti, M., & Ferrigno, A. (2022) · Biomedicines · doi:10.3390/biomedicines10010194 · Cited by 33
Liu, S., Yin, R., Yang, Z., Wei, F., & Hu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.971409 · Cited by 33
Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)—In Vitro Testing
Tátrai, P., Erdő, F., & Krajcsi, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010029 · Cited by 34
Preventing acute liver injury via hepatocyte‐targeting nano‐antioxidants
Xuejiao, Y., Zhou, Y., Sun, J., Wang, S., Hu, X., Li, J., Huang, J. B., & Chen, N. (2023) · Cell Proliferation · doi:10.1111/cpr.13494 · Cited by 33
UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis
Bessone, F., Hillotte, G. L., Ahumada, N., Jaureguizahar, F., Medeot, A. C., & Roma, M. G. (2024) · Seminars in Liver Disease · doi:10.1055/s-0044-1779520 · Cited by 32
Lee, B., Jung, E., Yoo, J., Kim, S. G., Lee, C., Kim, Y. S., Jeong, S. W., Jang, J. Y., Lee, S. H., Kim, H. S., et al. (2020) · Liver International · doi:10.1111/liv.14434 · Cited by 32
Zippi, M., Fiorino, S., Occhigrossi, G., & Hong, W. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i8.1385 · Cited by 32
Debureaux, P.-É., Bourrier, P., Rautou, P., Zagdanski, A., Boutiny, M. D., Pagliuca, S., Galy, A. S. D., Robin, M., de Latour, R. P., Plessier, A., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.245407 · Cited by 32
Weersink, R. A., Alvarez‐Alvarez, I., Medina‐Cáliz, I., Sanabria‐Cabrera, J., Robles‐Díaz, M., Ortega‐Alonso, A., García‐Cortés, M., Bonilla, E., Niu, H., Soriano, G., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2108 · Cited by 29
Self-citationPrevalence and risk factors of tigecycline-induced liver injury: A multicenter retrospective study
Yu, Z., Zhao, Y., Jin, J., Zhu, J., Yu, L., & Han, G. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.04.024 · Cited by 32
Cavaco, M. J., Alcobia, M. C. D. S., Oliveiros, B., Mesquita, L. A., Carvalho, A., Matos, F., Carvalho, J. M., Villar, M., Duarte, R., Mendes, J., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050790 · Cited by 32
Matthews, P. C., Campbell, C., Săndulescu, O., Matičič, M., Ruță, S. M., Rivero‐Juárez, A., van Welzen, B. J., Tan, B. K., García, F., Gherlan, G. S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1062408 · Cited by 32
COVID-19 and liver injury: An ongoing challenge
Papagiouvanni, I., Kotoulas, S., Pataka, A., Spyratos, D. G., Porpodis, Κ., Boutou, A., Papagiouvannis, G., Grigoriou, I., Vettas, C., & Goulis, I. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.257 · Cited by 32
Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM
Kobayashi, T., Iwaki, M., Nogami, A., & Yoneda, M. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00067s · Cited by 33
Vollmer, O., Felten, R., Mertz, P., Lebrun‐Vignes, B., Salem, J., & Arnaud, L. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102460 · Cited by 32
Irinotecan-Induced Steatohepatitis: Current Insights
Han, J., Zhang, J., & Zhang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.754891 · Cited by 31
Antipsychotic Safety in Liver Disease: A Narrative Review and Practical Guide for the Clinician
Gunther, M. G., & Dopheide, J. A. (2022) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2022.09.006 · Cited by 31
Kuyucu, S., Blanca‐López, N., Caubet, J., Moral, L., Sousa‐Pinto, B., Topal, Ö. Y., Mori, F., Atanasković‐Marković, M., & Gomes, E. R. (2025) · Pediatric Allergy and Immunology · doi:10.1111/pai.70103 · Cited by 31
Art of Making Artificial Liver: Depicting Human Liver Biology and Diseases in Mice
Sugahara, G., Ishida, Y., Sun, J. C., Tateno, C., & Saito, T. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1701444 · Cited by 31
Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
Hey‐Hadavi, J., Seekins, D. W., Palmer, M., Coffey, D., Caminis, J. N., Abdullaev, S., Patwardhan, M. B., Tyler, H., Raheja, R., Stanley, A. M., et al. (2021) · Drug Safety · doi:10.1007/s40264-021-01051-5 · Cited by 30
Self-citationWang, J., Qiu, Y., Yang, L., Wang, J., He, J., Tang, C., Yang, Z., Hong, W., Yang, B., He, Q., et al. (2024) · Autophagy · doi:10.1080/15548627.2024.2384348 · Cited by 30
Dietary Iron Overload Differentially Modulates Chemically-Induced Liver Injury in Rats
Mori, M., Izawa, T., Inai, Y., Fujiwara, S., Aikawa, R., Kuwamura, M., & Yamate, J. (2020) · Nutrients · doi:10.3390/nu12092784 · Cited by 30
Metwally, N. H., Mohamed, M. S., & Deeb, E. A. (2021) · Research on Chemical Intermediates · doi:10.1007/s11164-021-04564-x · Cited by 30
Lei, X., Xu, Q., Li, C., Niu, B., Ming, Y., Li, J., Tang, Y., Li, X., Tang, J. T., Wu, J., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.71781 · Cited by 30
Sloan‐Dennison, S., Scullion, K., Clark, B., Fineran, P., Mair, J., Laing, S., Shand, N. C., Rathmell, C., Creasey, D. J., Bingemann, D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61600-9 · Cited by 29
Drug Induced Liver Injury Attributed to a Curcumin Supplement
Imam, Z., Khasawneh, M., Jomaa, D., Iftikhar, H., & SayedAhmad, Z. (2019) · Case Reports in Gastrointestinal Medicine · doi:10.1155/2019/6029403 · Cited by 29
The complexity of T cell–mediated penicillin hypersensitivity reactions
Goh, S. J. R., Tuomisto, J. E. E., Purcell, A. W., Mifsud, N. A., & Illing, P. T. (2020) · Allergy · doi:10.1111/all.14355 · Cited by 29
Is there a need for liver enzyme monitoring in people using gender-affirming hormone therapy?
Stangl, T. A., Wiepjes, C. M., Defreyne, J., Conemans, E. B., Fisher, A. D., Schreiner, T., T'Sjoen, G. G., & den Heijer, M. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1064 · Cited by 29
Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity
Downes, K. J., & Goldman, J. L. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2190 · Cited by 29
Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries
Bessone, F., Ferrari, A., Hernández, N., Mendizábal, M., Ridruejo, E., Zerega, A. R., Tanno, F., Reggiardo, M. V., Vorobioff, J., Tanno, H., et al. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03419-7 · Cited by 29
Self-citationBiohybrid Response Microparticles Decorated with Trained‐MSCs for Acute Liver Failure Recovery
Wang, J., Huang, D., Yu, H., Ren, H., & Shang, L. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201085 · Cited by 28
Nash, E., Sabih, A., Chetwood, J., Wood, G., Pandya, K., Yip, T., Majumdar, A., McCaughan, G. W., Strasser, S. I., & Liu, K. (2021) · Medical Journal of Australia · doi:10.5694/mja2.51173 · Cited by 28
Guo, K., & van den Beucken, T. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01317-2 · Cited by 28
Delire, B., Martin, E. D., Meunier, L., Larrey, D. G., & Horsmans, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.786174 · Cited by 28
Self-citationTabaee, S. S., Sahebkar, A., Aghamohammadi, T., Pakdel, M., Dehabeh, M., Sobhani, R., Alidadi, M., Majeed, M. A., & Mirhafez, S. R. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73234-9_13 · Cited by 28
The Influence of Chronic Liver Diseases on Hepatic Vasculature: A Liver-on-a-chip Review
Özkan, A., Stolley, D. L., Cressman, E. N. K., McMillin, M., DeMorrow, S., Yankeelov, T. E., & Rylander, M. N. (2020) · Micromachines · doi:10.3390/mi11050487 · Cited by 28
Management of Pharmacologic Adverse Effects in Advanced Liver Disease
García‐Cortés, M., & García-García, A. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01150-w · Cited by 27
Dara, L., & Martin, E. D. (2025) · Liver International · doi:10.1111/liv.16198 · Cited by 27
Zimmer, L., Livingstone, E., Krackhardt, A. M., Schultz, E. S., Göppner, D., Assaf, C., Trebing, D., Stelter, K., Windemuth-Kieselbach, C., Ugurel, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.011 · Cited by 27
Welzel, T., Ellinghaus, M., Wildermuth, A. L., Deschner, N., Benseler, S. M., & Kuemmerle-Deschner, J. B. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.759664 · Cited by 27
Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies
Hernández, N., & Bessone, F. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00243 · Cited by 27
Nardo, M., Gouda, M. A., Nelson, B. E., BARRETO, C. M. N., Slade, J. H., Poullard, A., Zafereo, M., Hu, M. I.-N., Cabanillas, M. E., & Subbiah, V. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101332 · Cited by 27
Metadata
- Authors
- Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 70
- Issue
- 6
- Pages
- 1222-1261
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2924328881
- Semantic Scholar
- 6d774d1c570eef200451a1e8a8f5655c367a4eaf
- Cited by
- 1,276
- References
- 371
- Citations by year
- 2026: 243 · 2025: 211 · 2024: 175 · 2023: 159 · 2022: 158 · 2021: 184 · 2020: 117 · 2019: 27
- FWCI
- 78.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Cooperation in Science & Technology
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- drug-induced liver injury, idiosyncratic drug-induced liver injury, hepatotoxicity, acute liver failure, risk factors, diagnosis, risk minimization
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Histocompatibility Testing, Humans, Liver Neoplasms, Male, Middle Aged, Mitochondria, Risk Factors, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
